Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Texas Business Times.
Press releases published on August 25, 2025

MISSION PRODUCE® to Release Fiscal Third Quarter 2025 Financial Results on Monday, September 8, 2025
OXNARD, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced it will release its financial results for the …

RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference
ALISO VIEJO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in …

OrthoPediatrics Corp. Announces the Appointment of Kelly Fischer to its Board of Directors
WARSAW, Ind., Aug. 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Kelly Fischer to …

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, …

zSpace to Present at the 2025 Gateway Conference on September 4th
SAN JOSE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in immersive augmented reality (AR) solutions for education, is confirmed to present at the 2025 Annual Gateway Conference, which is being …

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, …

Navitas Semiconductor Names Chris Allexandre as President and Chief Executive Officer
Semiconductor veteran brings decades of experience in sales, operations and business leadership. Positions Navitas for expected growth in AI data center as well as energy infrastructure and other industrial markets poised for GaN- and SiC-based …

Rent the Runway to Report Second Quarter 2025 Results on September 11, 2025
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Rent the Runway, Inc. (“Rent the Runway”) (Nasdaq: RENT) announced today that it expects to release its second quarter 2025 financial results for the quarter ended July 31, 2025 on Thursday, September 11, 2025, …

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the …

BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biohaven Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

LINE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lineage, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

SOC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sable Offshore Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

FLYW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Flywire Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

LMT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lockheed Martin Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

Amlan® to Present on Biotoxin Control and Antibiotic-Free Poultry Production at Malaysia Livestock 2025
CHICAGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amlan International, the animal health business of Oil-Dri® Corporation of America and a global leader in natural feed additives, will participate in Malaysia Livestock 2025 at the Kuala Lumpur Convention Centre …

ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …

NEOG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …

AI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that C3.ai, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025 IND filing on first radio-DARPin …